{
    "nctId": "NCT02226276",
    "briefTitle": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer",
    "officialTitle": "A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Soft Tissue Metastases, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must be women who have histological confirmation of metastatic invasive breast cancer that has metastasized outside the region of the primary tumor and axilla; biopsy must be obtained prior to initiation of chemotherapy; it should be performed within 28 days prior to enrollment (patients with a biopsy of recurrent disease that is HER2-positive and have not received HER2-directed therapy since the biopsy can exceed the 28-day window up to 6 months); patients must have metastatic disease in lung, liver, soft-tissue or bone to qualify for the study (more than one site is permissible)\n* At least 1 site of metastasis \\>= 20 mm in mean diameter must be identified\n* The cancer must over express HER2 as determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH)\n* Patients may not have received trastuzumab within 6 weeks of projected 64Cu-DOTA-trastuzumab/PET-CT\n* Participants must have normal cardiac ejection fraction\n* Ability to provide informed consent\n* Patients that may need dose reduction to commence cycle 1 treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Negative serum pregnancy test (female of childbearing potential only)\n* Patients must have adequate cardiac function; left ventricular ejection fraction (LVEF) \\>= 50% as determined by multi gated acquisition (MUGA) scan or echocardiogram\n\nExclusion Criteria:\n\n* Participants who have received trastuzumab within the prior 36 days\n* Participants who are not considered candidates for ado-trastuzumab-emtansine\n* No metastatic sites \\>= 20 mm\n* Concurrent malignancy other than skin cancer - Inability to provide informed consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}